Criteo (CRTO) Competitors $44.02 -0.01 (-0.02%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends CRTO vs. HQY, GLOB, STN, BILI, WSC, LYFT, ETSY, MARA, QXO, and RELYShould you be buying Criteo stock or one of its competitors? The main competitors of Criteo include HealthEquity (HQY), Globant (GLOB), Stantec (STN), Bilibili (BILI), WillScot Mobile Mini (WSC), Lyft (LYFT), Etsy (ETSY), MARA (MARA), QXO (QXO), and Remitly Global (RELY). These companies are all part of the "business services" industry. Criteo vs. HealthEquity Globant Stantec Bilibili WillScot Mobile Mini Lyft Etsy MARA QXO Remitly Global Criteo (NASDAQ:CRTO) and HealthEquity (NASDAQ:HQY) are both mid-cap computer and technology companies, but which is the better business? We will contrast the two companies based on the strength of their community ranking, institutional ownership, analyst recommendations, risk, profitability, media sentiment, dividends, valuation and earnings. Is CRTO or HQY more profitable? HealthEquity has a net margin of 8.41% compared to Criteo's net margin of 5.08%. Criteo's return on equity of 16.37% beat HealthEquity's return on equity.Company Net Margins Return on Equity Return on Assets Criteo5.08% 16.37% 8.04% HealthEquity 8.41%9.70%6.08% Which has more volatility and risk, CRTO or HQY? Criteo has a beta of 1.05, suggesting that its stock price is 5% more volatile than the S&P 500. Comparatively, HealthEquity has a beta of 0.55, suggesting that its stock price is 45% less volatile than the S&P 500. Does the MarketBeat Community believe in CRTO or HQY? Criteo received 42 more outperform votes than HealthEquity when rated by MarketBeat users. However, 70.04% of users gave HealthEquity an outperform vote while only 66.94% of users gave Criteo an outperform vote. CompanyUnderperformOutperformCriteoOutperform Votes57566.94% Underperform Votes28433.06% HealthEquityOutperform Votes53370.04% Underperform Votes22829.96% Which has higher valuation and earnings, CRTO or HQY? HealthEquity has lower revenue, but higher earnings than Criteo. Criteo is trading at a lower price-to-earnings ratio than HealthEquity, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCriteo$1.93B1.26$53.26M$1.6826.18HealthEquity$999.59M9.88$55.71M$1.09104.53 Does the media favor CRTO or HQY? In the previous week, Criteo had 5 more articles in the media than HealthEquity. MarketBeat recorded 16 mentions for Criteo and 11 mentions for HealthEquity. HealthEquity's average media sentiment score of 0.95 beat Criteo's score of 0.82 indicating that HealthEquity is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Criteo 5 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive HealthEquity 7 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders believe in CRTO or HQY? 94.3% of Criteo shares are owned by institutional investors. Comparatively, 99.6% of HealthEquity shares are owned by institutional investors. 1.7% of Criteo shares are owned by company insiders. Comparatively, 2.2% of HealthEquity shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Do analysts prefer CRTO or HQY? Criteo presently has a consensus price target of $52.90, suggesting a potential upside of 20.25%. HealthEquity has a consensus price target of $110.71, suggesting a potential downside of 2.83%. Given Criteo's higher probable upside, research analysts clearly believe Criteo is more favorable than HealthEquity.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Criteo 0 Sell rating(s) 4 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.60HealthEquity 0 Sell rating(s) 1 Hold rating(s) 13 Buy rating(s) 0 Strong Buy rating(s) 2.93 SummaryHealthEquity beats Criteo on 10 of the 18 factors compared between the two stocks. Get Criteo News Delivered to You Automatically Sign up to receive the latest news and ratings for CRTO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CRTO vs. The Competition Export to ExcelMetricCriteoAdvertising agencies IndustryComputer SectorNASDAQ ExchangeMarket Cap$2.43B$2.18B$26.77B$9.17BDividend YieldN/A4.24%2.78%4.00%P/E Ratio26.1892.6241.7319.41Price / Sales1.2641.362,765.2780.83Price / Cash16.299.5236.8138.87Price / Book2.512.678.185.07Net Income$53.26M$130.42M$671.16M$222.90M7 Day Performance-4.14%0.15%1.89%0.31%1 Month Performance18.76%34.56%7.28%5.45%1 Year Performance38.95%-5.22%27.39%23.23% Criteo Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CRTOCriteo2.745 of 5 stars$43.99-0.1%$52.90+20.3%+37.6%$2.43B$1.93B26.183,563Insider TradeShort Interest ↑Analyst RevisionHQYHealthEquity2.888 of 5 stars$112.15+0.6%$110.71-1.3%+42.4%$9.72B$999.59M102.893,150Insider TradeGLOBGlobant4.0838 of 5 stars$216.28-0.5%$230.28+6.5%-8.9%$9.32B$2.35B56.4729,150Upcoming EarningsNews CoverageSTNStantec3.2022 of 5 stars$78.30+2.2%N/A-4.9%$8.93B$4.80B35.5928,000BILIBilibili1.2872 of 5 stars$18.34-0.9%$19.69+7.3%+83.6%$7.60B$3.19B-19.948,801WSCWillScot Mobile Mini3.9017 of 5 stars$37.69+1.3%$45.50+20.7%-28.5%$6.96B$2.36B342.695,000Positive NewsLYFTLyft4.8456 of 5 stars$15.13+6.7%$17.78+17.6%+6.9%$6.27B$4.40B-94.532,945Earnings ReportAnalyst ForecastBuyback AnnouncementOptions VolumeNews CoverageETSYEtsy4.4891 of 5 stars$54.15-0.5%$62.42+15.3%-33.1%$6.09B$2.80B27.632,420Positive NewsMARAMARA3.9463 of 5 stars$16.770.0%$25.67+53.1%-40.5%$5.69B$598.75M21.229QXOQXO1.9722 of 5 stars$13.42+1.0%N/AN/A$5.49B$54.52M-1.47195News CoverageRELYRemitly Global1.3562 of 5 stars$25.70+1.2%$23.75-7.6%+35.8%$5.09B$944.28M-73.432,700Upcoming Earnings Related Companies and Tools Related Companies HQY Competitors GLOB Competitors STN Competitors BILI Competitors WSC Competitors LYFT Competitors ETSY Competitors MARA Competitors QXO Competitors RELY Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CRTO) was last updated on 2/13/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredTop Picks for Trump’s Pro-Crypto America10,000% Crypto Opportunities in 2025 27 of the brightest minds in crypto share exclusive intel… Crypto 101 Media | SponsoredHe called the top and bottom of Bitcoin nearly to the day … Here’s what he says is next.With Donald Trump’s return to the oval office, the war on crypto is over. The digital currency is not only ...Weiss Ratings | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredWhy Buffett and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Criteo S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Criteo With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.